Glioblastoma is a particularly aggressive brain tumor that at present is incurable. Cancer doctors can extend patients' life expectancy through operations, radiation, chemotherapy or surgical interventions. Nevertheless, half of patients die within twelve months of diagnosis.

In a study published in Nature Nanotechnology, researchers discovered that cuproptosis may serve as a new target for radiosensitization in re-irradiation.

Experts believe they may have discovered an unlikely yet accessible treatment for the brain cancer glioblastoma - a little-known antidepressant called vortioxetine.

The findings raise hope for treating an aggressive disease, which currently has a survival time of just 12-18 months

Lab tests on cancer cells have shown it was “unexpectedly effective” in treating glioblastomas

In a study published in Advanced Functional Materials, a research team from the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences developed an oral molecular targeted drug ...

Researchers confirm plasma pTau181 is a strong predictor for Alzheimer's in patients with mild cognitive impairment, offering a less invasive diagnostic tool for early intervention.

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of HER2-negative cancers varies among patients, so one goal is to be able to classify tumors in more detail and thus determine the best treatment for each case.

In the treatment of cancer patients, irradiation can be adapted anew each day to the position of the tumor and conditions in the body.

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers.

By tracking the changes in prostate cancer cells over time, researchers at the Johns Hopkins Kimmel Cancer Center have found that activation of the MYC gene -; a well-known cancer-causing gene -; sets off a cascade of events that leads to both initiation and progression of the disease.

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

There is a challenge related to prostate and many other cancers that cancer cells form resistance to treatments as the disease progresses. However, these resistance mechanisms are not yet fully understood. A new study found that inflammation-promoting immune cells, M1 macrophages, can transform cancer cells into stem-like cells and thus immune to treatment.

Researchers have used a drug screening platform they developed to show that an antidepressant, currently on the market, kills tumor cells in the dreaded glioblastoma -- at least in the cell-culture dish.

Investigators developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient. By using 3D mini tumor models that closely resemble a patient's tumor, treatments could be tailored more effectively, paving the way for more personalized cancer treatments.

Using a fungus' own tricks against it...

The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD) despite the Stroke Prevention Trial in Sickle Cell Anemia (STOP) establishing standards of care like transfusions and tests to measure blood flow in the brain for those deemed high-risk, according to a new study.

A multi-institutional clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.

A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and The University of Texas M.D. Anderson Cancer Center, have reported safety and efficacy results from a Phase 1 trial that featured a personalized vaccine to treat lymphoplasmacytic lymphoma, a rare and slow-growing type of blood cancer, according to a study published recently in Nature Communications.

In the complex landscape of cancer, tumors create their own microenvironment, often marked by low oxygen levels, a condition known as hypoxia.